Revenue from operations grew 14% at Rs. 426 cr. against Rs. 372 cr.
Ajanta Pharma Board of Directors approved Q4 & FY 2016 results.
Q4 FY 2016 performance highlights (Consolidated)
Revenue from operations grew 14% at Rs. 426 cr. against Rs. 372 cr.
EBITDA growth of 6% at Rs. 141 cr. against Rs. 133 cr., EBITDA at 33% of revenue.
Profit before tax grew 14% at Rs. 131 cr. against Rs. 115 cr.
Profit after tax grew 43% at Rs. 106 cr. against Rs. 74 cr., PAT at 25% of revenue
FY 2016 performance highlights (Consolidated)
Revenue from operations grew 17% at Rs. 1,728 cr. against Rs. 1,474 cr.
EBITDA growth of 15% at Rs. 581 cr. against Rs. 505 cr., EBITDA at 34% of revenue.
Profit before tax grew 20% at Rs. 547 cr. against Rs. 456 cr.
Profit after tax grew 30% at Rs. 401 cr. against Rs. 310 cr., PAT at 23% of revenue.
No comments:
Post a Comment